This inventor holds 2 USPTO granted patents and 1 published patent application and 2 EPO patents. Top assignee: Cardiopolymers, Inc.. Active years: 2011-2013.
Company Filing History:
Years Active: 2011-2013
Title: Mark Maciejewski: Innovator in Cardiac Treatment
Introduction
Mark Maciejewski is a notable inventor based in Edina, MN (US). He has made significant contributions to the field of cardiac treatment, particularly in the management of cardiac arrhythmias. With a total of 2 patents, his work focuses on innovative methods to improve patient outcomes in cardiac care.
Latest Patents
One of Mark's latest patents is titled "Treatment of cardiac arrhythmia by modification of neuronal signaling through fat pads of the heart." This invention aims to control cardiac arrhythmias, such as atrial fibrillation, post-operatively. The method involves introducing various non-ablative agents, including polymers, fibroblasts, neurotoxins, and growth factors, into one or more cardiac fat pads. These agents are introduced into the atrioventricular nodal fat pad, which is in proximity to the autonomic ganglia. The technique for introducing the agent can include injection, and the target sites are identified using a stimulator with electrodes.
Career Highlights
Mark Maciejewski is associated with Cardiopolymers, Inc., where he continues to develop and refine his innovative approaches to cardiac treatment. His work is characterized by a commitment to advancing medical technology and improving patient care.
Collaborations
Some of Mark's notable coworkers include Todor N Mazgalev and Nicholas S Peters. Their collaboration contributes to the innovative environment at Cardiopolymers, Inc., fostering advancements in cardiac treatment.
Conclusion
Mark Maciejewski is a distinguished inventor whose work in cardiac treatment is paving the way for new therapeutic approaches. His patents reflect a deep understanding of the complexities of cardiac arrhythmias and a dedication to improving patient outcomes.